Bravelle Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Bravelle market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising demand for ovulation induction therapies, government support for fertility treatments, expanded healthcare access in emerging markets, growing acceptance of fertility preservation techniques, and the availability of non-invasive treatment options.

Growth during the market's forecast will be driven by the increasing popularity of natural and alternative therapies, the expansion of healthcare infrastructure in emerging economies, heightened awareness of fertility preservation among younger populations, broader healthcare insurance coverage for fertility treatments, and growing social acceptance of assisted reproductive technologies. Key trends expected to shape the market include advancements in artificial intelligence and machine learning for IVF procedures, the integration of genetic screening with assisted reproductive technologies (ART) to improve success rates, a growing focus on male infertility treatments, the incorporation of digital health solutions, and an emphasis on holistic approaches.

The increasing rates of infertility are expected to drive the growth of the bravelle market in the future. Infertility is defined as the inability to conceive after a year or more of regular unprotected intercourse or to carry a pregnancy to full term. Factors such as changing lifestyles, delayed family planning, higher stress levels, and environmental challenges contribute to the rise in infertility rates. Bravelle helps address infertility by stimulating the ovaries to produce multiple eggs, improving the chances of successful fertilization and pregnancy, especially for women with ovulatory disorders or those undergoing assisted reproductive techniques such as IVF. For example, in February 2024, the Office for National Statistics in the UK reported that the total fertility rate (TFR) in 2022 had fallen to 1.49 children per woman, down from 1.55 in 2021. Thus, the rising infertility rates are driving the growth of the bravelle market.

The growing demand for personalized medicine is also expected to contribute to the market’s expansion. Personalized medicine involves tailoring medical treatments to an individual's specific characteristics, such as genetics, lifestyle, and environment, to enhance treatment effectiveness. The demand for personalized medicine is increasing due to advances in genomics, a growing emphasis on precision healthcare, and rising awareness about the benefits of individualized treatments. Bravelle, a recombinant form of follicle-stimulating hormone (FSH), helps personalize fertility treatment by stimulating ovarian follicle growth, enabling customized protocols that adjust to individual responses for optimal egg production and improved chances of pregnancy success. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. The new treatments included seven cancer drugs and three for other diseases. Therefore, the increasing demand for personalized medicine is fueling the growth of the bravelle market.

In April 2023, Ferring International Center S.A., a Switzerland-based biopharmaceutical company that specializes in Bravelle, entered into a partnership with BII Holdings A/S. This collaboration aims to accelerate innovation in women’s health by supporting early-stage startups and projects in reproductive medicine, addressing the underinvestment in female-specific healthcare. BII Holdings A/S is a Denmark-based biotechnology startup that focuses on providing innovative solutions in the life sciences and biotechnology sectors.

The key company operating in the bravelle market is Ferring Pharmaceuticals.

North America was the largest region in the bravelle market in 2024. The regions covered in bravelle report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bravelle market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bravelle is a purified human follicle-stimulating hormone (FSH) treatment used in fertility treatments, especially for women undergoing in vitro fertilization (IVF). It aids in stimulating the ovaries to produce multiple eggs, which is essential for successful IVF procedures, and is commonly prescribed to women who struggle with egg production. It is frequently combined with other fertility medications to increase the chances of pregnancy.

The main segments of the bravelle market include fresh in vitro fertilization (IVF) cycles, thawed IVF cycles, and donor egg IVF cycles. A fresh IVF cycle involves collecting eggs from a woman's ovaries, fertilizing them with sperm in the lab, and transferring the resulting embryos into the uterus. The various techniques utilized in these cycles include in vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo transfer (FET), and other related procedures. Bravelle is applied in human reproduction, as well as research and reproductive toxicology, and is used by a range of end users, including fertility clinics, hospitals, surgical centers, and clinical research institutes.

The bravelle market research report is one of a series of new reports that provides bravelle market statistics, including bravelle industry global market size, regional shares, competitors with a bravelle market share, detailed bravelle market segments, market trends and opportunities, and any further data you may need to thrive in the bravelle industry. This bravelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bravelle market consists of sales of bravelle 75 iu injection, bravelle 100 iu injection, and bravelle urofollitropin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.